Compile Data Set for Download or QSAR
Report error Found 35 Enz. Inhib. hit(s) with all data for entry = 3223
TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350338BDBM350338((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)-8-fluoro...)
Affinity DataIC50: 1.26nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350339BDBM350339((S)-3-(1-((1-acryloylpyrrolidin-3-yl)amino)-8-fluo...)
Affinity DataIC50: 1.26nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350340BDBM350340((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)-7-chloro...)
Affinity DataIC50: 1.26nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350343BDBM350343(US9801872, Example 27 | (S)-3-(1-((1-acryloylpyrro...)
Affinity DataIC50: 1.26nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350321BDBM350321((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50: 2nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350324BDBM350324((S)-3-(1-((1-acryloylpyrrolidin-3-yl)amino)isoquin...)
Affinity DataIC50: 2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350341BDBM350341(US9801872, Example 25 | (S)-3-(1-((1-acryloylpyrro...)
Affinity DataIC50: 2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350350BDBM350350(US9801872, Example 34 | (S)-5-(1-((1-(2-chloroacet...)
Affinity DataIC50: 2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350336BDBM350336(3-(1-(((3R,4S)-1-acryloyl-4-methylpyrrolidin-3-yl)...)
Affinity DataIC50: 2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350346BDBM350346(US9801872, Example 30 | (S)-3-(6-((1-acryloylpyrro...)
Affinity DataIC50: 2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350333BDBM350333((S)-3-(8-((1-acryloylpyrrolidin-3-yl)amino)-1,7-na...)
Affinity DataIC50: 2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350342BDBM350342(US9801872, Example 26 | (S)-3-(1-((1-acryloylpyrro...)
Affinity DataIC50: 2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350344BDBM350344(US9801872, Example 28 | (S)-3-(1-((1-acryloylpyrro...)
Affinity DataIC50: 2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350345BDBM350345(US9801872, Example 29 | (S)-3-(1-((1-acryloylpyrro...)
Affinity DataIC50: 2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350332BDBM350332((S)-3-(8-((1-acryloylpyrrolidin-3-yl)oxy)-1,7-naph...)
Affinity DataIC50: 3.16nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350327BDBM350327((S)-3-(1-((1-acryloylpyrrolidin-3-yl)(methyl)amino...)
Affinity DataIC50: 3.16nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350348BDBM350348(US9801872, Example 32 | (S)-3-(6-((1-acryloylpyrro...)
Affinity DataIC50: 5.01nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350334BDBM350334((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)-7-fluoro...)
Affinity DataIC50: 6.31nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350335BDBM350335(3-(1-(((3R,4S)-1-acryloyl-4-methylpyrrolidin-3-yl)...)
Affinity DataIC50: 6.31nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350330BDBM350330((S,E)-5-(1-((1-(4-(dimethylamino)but-2-enoyl)pyrro...)
Affinity DataIC50: 6.31nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350349BDBM350349(US9801872, Example 33 | (S)-5-(1-((1-(2-chloroacet...)
Affinity DataIC50: 6.31nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350320BDBM350320(N-(1-(3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)i...)
Affinity DataIC50: 7.94nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350322BDBM350322((S)-3-(1-(((1-acryloylpyrrolidin-2-yl)methyl)amino...)
Affinity DataIC50: 10nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350323BDBM350323((S)-3-(1-((1-acryloylpyrrolidin-2-yl)methoxy)isoqu...)
Affinity DataIC50: 10nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350329BDBM350329((S)-3-(1-(((1-acryloylpyrrolidin-3-yl)oxy)methyl)i...)
Affinity DataIC50: 10nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350325BDBM350325((R)-3-(1-((1-acryloylpyrrolidin-2-yl)methoxy)isoqu...)
Affinity DataIC50: 12.6nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350331BDBM350331((S,E)-3-(1-((1-(but-2-enoyl)pyrrolidin-3-yl)amino)...)
Affinity DataIC50: 25.1nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350351BDBM350351(US9801872, Example 35 | (S)-5-(1-((1-acryloylpiper...)
Affinity DataIC50: 31.6nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350326BDBM350326((S)-3-(1-((1-methacryloylpyrrolidin-3-yl)amino)iso...)
Affinity DataIC50: 31.6nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350347BDBM350347(US9801872, Example 31 | (S)-3-(6-((1-acryloylpyrro...)
Affinity DataIC50: 63.1nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350318BDBM350318((R)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50: 79.4nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350335BDBM350335(3-(1-(((3R,4S)-1-acryloyl-4-methylpyrrolidin-3-yl)...)
Affinity DataIC50: 126nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350328BDBM350328((S)-3-(1-((1-methacryloylpyrrolidin-3-yl)oxy)isoqu...)
Affinity DataIC50: 126nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350317BDBM350317((R)-3-(1-((1-methacryloylpyrrolidin-3-yl)oxy)isoqu...)
Affinity DataIC50: 200nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandChemical structure of BindingDB Monomer ID 350319BDBM350319((R,E)-3-(1-((1-(but-2-enoyl)pyrrolidin-3-yl)oxy)is...)
Affinity DataIC50: 316nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
US Patent